Biolevate lands €30M Series A to scale life sciences AI

Paris-based Biolevate, an AI company specializing in life sciences, has secured €30 million in Series A funding to scale its platform that automates scientific and regulatory workflows. The investment round was led by RAISE France and Orange Ventures, with support from MSD Global Health Innovation Fund, Station F, and EQT Ventures.

Biolevate, founded by ex-Dataiku engineers and AI researchers, aims to address operational challenges in the life sciences industry. The company's enterprise agentic AI platform converts scientific and regulatory knowledge into auditable workflows, ensuring outputs are based on evidence while allowing human oversight in regulated environments.

Initially designed to expedite regulatory approval workflows, Biolevate's platform now covers various aspects of the life sciences value chain, from research and clinical trials to health technology assessments, regulatory dossiers, drug discovery, and development. The platform can handle up to 100,000 agents concurrently. Biolevate claims its platform has increased systematic literature review and research synthesis speeds by sixteenfold and achieved an 80% efficiency gain in regulatory intelligence and compliance.

Since its seed round in 2024, Biolevate has expanded its partnerships and customer base across the life sciences sector, now serving more than a dozen enterprise customers and witnessing growth in annual recurring revenue. Co-founder and CEO Joël Belafa expressed his team's mission-driven commitment, stating that AI can significantly improve lives when empowered with the right people and tackled with the right technological challenges.

The new funding and Biolevate's recent growth reinforce the company's plans to scale globally and expand AI use in healthcare. With the Series A funding, Biolevate is set to enter the US market, opening an office in Boston and doubling its headcount over the past year. The company anticipates doubling its workforce again within the next year and has filed seven patent applications across several therapeutic areas, with two filed in Europe.